
Yahoo · 29 de jul de 2026
Biogen’s growth portfolio, which includes one closely watched Alzheimer’s drug, is a bright spot in the second quarter.
Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Últimos 169 días · 12/11/25 — 27/07/26
+21.48%
Precio de cierre en pesos argentinos. Fuente: data912.
Precio
$ 20.850
Var. %
0%
Precio AMGN
US$ 393,44
Teórico (precio / ratio)
AMGN ÷ 30
US$ 13,11
Cotización
US$ 13,40
vs teórico
+2,18%
Cotización MEP implícita
$ 1.555,97
Cotización
US$ 13,32
vs teórico
+1,57%
Cotización Cable implícita
$ 1.565,32
Sí, existe el CEDEAR de AMGN (Amgen Inc.) en la Bolsa de Comercio de Buenos Aires (BYMA). Su ticker local es AMGN.
El ticker del CEDEAR de Amgen Inc. en Argentina es AMGN. La acción subyacente cotiza en NASDAQ con el símbolo AMGN.
El CEDEAR AMGN tiene un ratio de 30:1. Eso significa que 30 CEDEARs equivalen a 1 acción de AMGN.
El CEDEAR AMGN cotiza hoy a $ 20.850 en pesos argentinos, con una variación diaria de 0%.
La acción subyacente AMGN (Amgen Inc.) cotiza a US$ 393,44 en su mercado de origen (NASDAQ).
El precio teórico del CEDEAR AMGN se calcula dividiendo el precio de AMGN por el ratio (30). Hoy resulta en US$ 13,11.
En BYMA podés operar AMGN en pesos, AMGND en dólar MEP y AMGNC en dólar cable. Cada modalidad refleja un tipo de cambio distinto.
En esta página encontrás un gráfico con el precio histórico del CEDEAR AMGN en pesos argentinos, con datos de data912.

Yahoo · 29 de jul de 2026
Biogen’s growth portfolio, which includes one closely watched Alzheimer’s drug, is a bright spot in the second quarter.

Yahoo · 28 de jul de 2026
Amgen (NASDAQ:AMGN) today announced that it will report its second quarter 2026 financial results on Tuesday, August 4, 2026, after the close of the U.S. financ…

Yahoo · 28 de jul de 2026
One of the market's strongest health care performers barely moves with the index you already own, and that gap is the whole point.

ChartMill · 28 de jul de 2026
Stay updated with the movement of dow jones stocks in today's session. Discover which dow jones stocks are making waves on Tuesday.

ChartMill · 28 de jul de 2026
Join us in exploring the top gainers and losers within the dow jones index in the middle of the day on Tuesday as we examine the latest happenings in today's se…

Yahoo · 28 de jul de 2026
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expec…

Yahoo · 28 de jul de 2026
Wall Street's sweeping semiconductor sell-off deepened as investors move into the Dow's blue-chip names

ChartMill · 27 de jul de 2026
Let's have a look at the top dow jones gainers and losers one hour before the close of the markets of today's session.
Noticias vía Finnhub